Announced Date: 2025-10-28 (October 28, 2025)
Asset Name: QX031N
Licensor (Seller): Qyuns Therapeutics (China)
Licensee (Buyer): Roche
.
Asset Modality: Bispecific antibody (BsAb)
Asset Target: TSLP/IL-33
Potential Indication: Asthma and COPD
Current Stage: IND Enabling
.
Scope of Authority:
Qyuns Therapeutics grants Roche the global exclusive right to develop, manufacture, and commercialize QX031N.
.
Payment Detail:
Qyuns Therapeutics will receive:
upfront payment of US$75 million,
up to US$995 million milestone payments,
tiered royalties on potential future product sales
.
Link:
.
Note:
Chinese Name of Qyuns Therapeutics, 荃信生物
